CSPC Pharmaceutical Group Gelecekteki Büyüme

Future kriter kontrolleri 0/6

CSPC Pharmaceutical Group kazanç ve gelirin sırasıyla yıllık 1.4% ve 3.7% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 1.5% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 13.6% olacağı tahmin edilmektedir.

Anahtar bilgiler

1.4%

Kazanç büyüme oranı

1.5%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	19.7%
Gelir büyüme oranı	3.7%
Gelecekteki özkaynak getirisi	13.6%
Analist kapsamı	Good
Son güncelleme	29 Jan 2024

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

BMV:1093 N - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	31,695	4,650	6,184	N/A	3
12/31/2025	38,278	7,256	6,277	N/A	24
12/31/2024	35,198	6,738	6,097	N/A	27
12/31/2023	32,036	6,162	5,281	N/A	25
9/30/2023	31,306	6,118	N/A	N/A	N/A
6/30/2023	31,407	6,092	1,985	4,690	N/A
3/31/2023	31,116	6,116	N/A	N/A	N/A
12/31/2022	30,937	6,091	4,922	7,627	N/A
9/30/2022	30,721	5,738	N/A	N/A	N/A
6/30/2022	29,655	5,509	4,098	6,151	N/A
3/31/2022	29,007	5,538	N/A	N/A	N/A
12/31/2021	27,867	5,605	2,887	4,637	N/A
9/30/2021	26,369	5,977	N/A	N/A	N/A
6/30/2021	26,175	5,908	5,865	7,053	N/A
3/31/2021	25,551	5,472	N/A	N/A	N/A
12/31/2020	24,942	5,160	5,362	6,740	N/A
9/30/2020	24,558	4,421	N/A	N/A	N/A
6/30/2020	23,515	4,150	3,129	4,614	N/A
3/31/2020	22,735	3,922	N/A	N/A	N/A
12/31/2019	22,103	3,714	1,835	3,784	N/A
9/30/2019	21,335	3,625	N/A	N/A	N/A
6/30/2019	20,135	3,454	1,370	3,743	N/A
3/31/2019	18,835	3,294	N/A	N/A	N/A
12/31/2018	17,717	3,081	1,922	3,795	N/A
9/30/2018	16,877	2,905	N/A	N/A	N/A
6/30/2018	15,729	2,734	1,827	3,352	N/A
3/31/2018	13,959	2,443	N/A	N/A	N/A
12/31/2017	12,877	2,307	1,729	2,738	N/A
9/30/2017	12,203	2,195	N/A	N/A	N/A
6/30/2017	11,659	2,068	N/A	2,811	N/A
3/31/2017	11,383	1,979	N/A	N/A	N/A
12/31/2016	11,075	1,881	N/A	2,611	N/A
9/30/2016	10,439	1,711	N/A	N/A	N/A
6/30/2016	10,118	1,607	N/A	2,147	N/A
3/31/2016	9,656	1,473	N/A	N/A	N/A
12/31/2015	9,545	1,395	N/A	1,884	N/A
9/30/2015	9,284	1,305	N/A	N/A	N/A
6/30/2015	9,072	1,192	N/A	1,192	N/A
3/31/2015	8,919	1,126	N/A	N/A	N/A
12/31/2014	8,762	1,015	N/A	1,445	N/A
9/30/2014	8,423	896	N/A	N/A	N/A
6/30/2014	8,197	849	N/A	1,059	N/A
3/31/2014	8,001	814	N/A	N/A	N/A
12/31/2013	7,768	760	N/A	636	N/A
9/30/2013	7,345	1,967	N/A	N/A	N/A
6/30/2013	6,156	1,927	N/A	550	N/A
3/31/2013	4,818	1,806	N/A	N/A	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 1093 N 'nin tahmini kazanç büyümesi (yıllık 1.4% ) tasarruf oranının ( 7.7% ) altındadır.

Kazançlar ve Piyasa: 1093 N şirketinin kazançlarının (yıllık 1.4% ) MX pazarından (yıllık 12.6% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 1093 N şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: 1093 N şirketinin gelirinin (yıllık 3.7% ) MX pazarından (yıllık 7.2% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 1093 N şirketinin gelirinin (yıllık 3.7% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 1093 N 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 13.6 %).

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/02/12 01:25
Gün Sonu Hisse Fiyatı	2023/11/15 00:00
Kazançlar	2023/09/30
Yıllık Kazançlar	2022/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

CSPC Pharmaceutical Group Limited 50 Bu analistlerden 27, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Wai Chak Yuen	BOCI Research Ltd.
Sharon Shi	BOCI Research Ltd.
Ethan Cui	BofA Global Research

CSPC Pharmaceutical Group Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval for SYH2062 Injection

CSPC Pharmaceutical Group Limited Announces SYS6005 (Antibody-Drug Conjugate) Obtains Clinical Trial Approval

CSPC Pharmaceutical Group Limited Announces Board Changes

CSPC Pharmaceutical Group Limited to Report Nine Months, 2024 Results on Nov 15, 2024

CSPC Pharmaceutical Group Limited Announces Omalizumab for Injection Obtains Marketing Approval from NMPA

CSPC Pharmaceutical Group Limited Announces Valsartan Levoamlodipine Maleate Tablets Obtains Clinical Trial Approval

CSPC Pharmaceutical Group Limited (SEHK:1093) announces an Equity Buyback for HKD 5,000 million worth of its shares.

CSPC Pharmaceutical Group Limited Announces Aprepitant Injection Obtains Drug Registration Approval

CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2024, Payable on 20 November 2024

CSPC Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 21, 2024

CSPC Pharmaceutical Group Limited Obtains Approval from the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Announces Enlonstobart Injection Obtains Conditional Marketing Approval

CSPC Pharmaceutical Group Limited Obtains Approval from National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Approves Final Dividend for the Year Ended December 31, 2023

CSPC Pharmaceutical Group Limited Announces Recombinant Fully Human Anti-bKlotho Monoclonal Antibody Drug (JMT202) Obtains Approval from National Medical Products Administration of the People's Republic of China

CSPC Pharmaceutical Group Limited to Report Q1, 2024 Results on May 27, 2024

CSPC Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023

CSPC Pharmaceutical Group Limited Announces Highly Selective Mat2A Inhibitor (SYH2039) Obtains Clinical Trial Approval in the U.S

CSPC Pharmaceutical Group Limited Announces Dapagliflozin Tablets Obtains Drug Registration Approval

CSPC Pharmaceutical Group Limited, Annual General Meeting, May 28, 2024

CSPC Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 26 June 2024

CSPC Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024

CSPC Pharmaceutical Group Limited's Bispecific Fusion Protein Drug JMT106 Obtains Clinical Trial Approval from the U.S. Food and Drug Administration

CSPC Pharmaceutical Group Limited Announces Submission of New Drug Application for Irinotecan Liposome Injection to U.S. FDA

CSPC Pharmaceutical Group Limited Obtains Approval for Dextromethorphan Hydrobromide and Quinidine Sulphate Orally Disintegrating Tablets

CSPC Pharmaceutical Group Limited Announces Bivalent Covid-19 MRNA Vaccine (SYS6006.32) Included for Emergency Use in China

CSPC Pharmaceutical Group Limited Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited to Report Nine Months, 2023 Results on Nov 30, 2023

CSPC Pharmaceutical Group Limited's ALMB-0166 Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Phase II Clinical Trial Evaluating its Efficacy and Safety in Patients with Acute Ischemic Stroke in China

New major risk - Earnings quality

Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. Jointly Receive Breakthrough Therapy Designation on KN026 by CDE

CSPC Pharmaceutical Group Limited Obtains Approval Granted by the National Medical Products Administration of the People's Republic of China

CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval

CSPC Pharmaceutical Group Limited Announces NBL-028 for the Treatment of Advanced Tumors

CSPC Pharmaceutical Group Limited Announces Biologic License Application Approval for Narlumosbart for Injection (JMT103) by the NMPA

CSPC Pharmaceutical Group Limited Announces Semaglutide Injection Obtains Clinical Trial Approval

CSPC Pharmaceutical Group Limited Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China

CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2023, Payable on 12 October 2023

CSPC Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 23, 2023

Cspc Pharmaceutical Group Limited Announces Biologic License Application of Batoclimab (Hbm9161)

CSPC Ouyi Pharmaceutical Co., Ltd. Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China

CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval Granted by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

Cspc Pharmaceutical Group Limited Announces That Clinical Trial Application for Cpo301

Elevation Oncology Inc. Together with CSPC Pharmaceutical Group Limited Announce Promising Initial Clinical Data for SYSA1801 (EO-3021) from the Ongoing Phase 1 Dose Escalation and Expansion Study in China

Elevation Oncology Highlights First-In-Human Phase 1 Sysa1801 (Eo-3021) Clinical Data to Be Presented by Partner Cspc Pharmaceutical Group Limited At Asco 2023

CSPC Pharmaceutical Group Limited Declares Final Dividend for the Year Ended 31 December 2022

CSPC Pharmaceutical Group Limited to Report Q1, 2023 Results on May 25, 2023

Full year 2022 earnings released: EPS: CN¥0.51 (vs CN¥0.47 in FY 2021)

CSPC Pharmaceutical Group Limited Announces Highly Selective PRMT5 Inhibitor SYH2045 Obtains Clinical Trial Approval

Cspc Pharmaceutical Group Limited Announces ALMB-0166 for the Treatment of Osteoarthritis Obtains Clinical Trial Approval

CSPC Pharmaceutical Group Limited Receives Approval for SYH2043 from National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Announces NBL-020 for the Treatment of Advanced Solid Tumors Obtains Clinical Trial Approval in the U.S

Cspc Pharmaceutical Group Limited Announces That Syh2055 Developed by the Group Has Obtained Approval Granted by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Announces Antibody-Drug Conjugate CPO204 Obtains Clinical Trial Approval in the U.S

Third quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.11 in 3Q 2021)

CSPC Pharmaceutical Group Limited's SYHX1901 Tablets Obtains Approval Granted by the National Medical Products Administration

CSPC Pharmaceutical Group Limited Announces New Indication Application for Marketing Approval of Mingfule

CSPC Pharmaceutical Group Limited to Report Nine Months, 2022 Results on Nov 23, 2022

CSPC Pharmaceutical Group Limited Appoints Li Quan as an Independent Non-Executive Director

CSPC Pharmaceutical Group Limited Announces the Antibody-Drug Conjugate Sys6002

CSPC Pharmaceutical Group Limited Announces TG103 Injection Obtains Clinical Trial Approval for the Treatment of Non-Alcoholic Steatohepatitis

Upcoming dividend of HK$0.10 per share

CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2022, Payable on 11 October 2022

Second quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.13 in 2Q 2021)

CSPC Pharmaceutical Group Limited Announces Completion of Clinical Study of Heterologous Booster Immunization of SARS-CoV-2 mRNA Vaccine

Cspc Pharmaceutical Group Limited Announces Selective Ntrk and Ros1 Dual Inhibitor Syhx2009 Obtains Clinical Trial Approval

CSPC Pharmaceutical Group Limited Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China

Cspc Pharmaceutical Group Limited Obtains Duoenda (Mitoxantrone Hydrochloride Liposome Injection) Clinical Trial Approval for the Treatment of Neuromyelitis Optica Spectrum Disorders

CSPC Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 24, 2022

CSPC Pharmaceutical Group Announces Resignation of Wu Guizhen as Independent Non-Executive Director

CSPC Pharmaceutical Group Limited Announce Biologic License Application for Jmt103 Accepted by the NMPA

First quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.12 in 1Q 2021)

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri